Patrick Henrick

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

Justin M. Watts, Maria R. Baer, Jay Yang et al. · The Lancet Haematology · 2022 · 117 citations · Full text

Medicine, Hematology, Pharmacology +15

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

Irene M. Ghobrial, Chia‐Jen Liu, Robert Redd et al. · Clinical Cancer Research · 2019 · 101 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma

Irene M. Ghobrial, Chia‐Jen Liu, Oksana Zavidij et al. · American Journal of Hematology · 2019 · 61 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

Jacob P. Laubach, Chia‐Jen Liu, Noopur Raje et al. · Clinical Cancer Research · 2018 · 42 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Irene M. Ghobrial, Ashraf Badros, James J. Vredenburgh et al. · Blood · 2016 · 34 citations

Medicine, Oncology, Pharmacotherapy +13